Claude Skill

pipeline-devices

Device pipeline analysis: feasibility and pivotal study stages, design-iteration cycles, RWE studies, and post-market obligations, with reimbursement-aware value framing and decision-track awareness across the med universe.

LLM Mart · 0 points · 0 views 0 listing impressions 0 install-command copies
Virus-scanned Reviewed automatically before listing.

Full trust report

Download agentii-ai-agentii-investment-intelligence-plugins_vertical-plugins_bio-pharm_skills_agentii_pipeline-devices-3b0a195.zip · 5 KB
Part of agentii-ai/agentii-investment-intelligence — 46 skills

Install

skills CLI npx skills add https://github.com/agentii-ai/agentii-investment-intelligence/tree/main/plugins/vertical-plugins/bio-pharm/skills/agentii/pipeline-devices
Claude Code claude plugin marketplace add https://llmmart.ai/marketplace.json && claude plugin install agentii-ai-agentii-investment-intelligence@llmmart
Git git clone https://github.com/agentii-ai/agentii-investment-intelligence.git

The skills CLI installs just this skill, for any of its supported agents. Claude Code installs the whole agentii-ai/agentii-investment-intelligence collection as a plugin from our marketplace. Git is the plain clone.

Skill manifest

Methodology inspired by publicly taught medtech pipeline frameworks; all text is an original paraphrase.

Defaults

Parameter Default Value Rationale
asset_scope all disclosed devices Full-pipeline enumeration first
stage_lens feasibility + pivotal Design-iteration stages, not drug-phase labels
reimbursement_aware true Value framed against coverage paths, not raw approval
post_market_scan true Obligations and surveillance state surfaced
value_frame risk-adjusted Modeled value = unadjusted peak x POS, both shown

Preflight

Run canonical pre-flight per contracts/preflight.md. Propagate X-Agentii-Trace per contracts/x-agentii-trace-header.md. Confirm ticker resolution via search_companies before asset queries.

Triggers

  • "Analyze [ticker]'s device pipeline."
  • "What is in [ticker]'s feasibility and pivotal portfolio?"
  • "Where is each of [ticker]'s devices in its design cycle?"
  • "Which of [ticker]'s programs are approaching submission?"
  • "What RWE studies support [ticker]'s devices?"
  • "What post-market obligations does [ticker] carry?"
  • "Risk-adjust [ticker]'s device pipeline."
  • "What is the next catalyst for each of [ticker]'s devices?"
  • "How does [ticker]'s device pipeline compare to peers?"
  • "Which device classifications (PMA/De Novo/510(k)) map to [ticker]'s pipeline?"
  • "Map [ticker]'s devices by clinical stage and indication."
  • "What does [ticker]'s pipeline say about its reimbursement path?"

Production Grounding

  • Device stage ladder: feasibility (first-in-human, small N) → pivotal (registrational) → submission (PMA / De Novo / 510(k)) → post-market. Devices iterate through design versions; design freezes and iteration cycles are the pipeline milestones, not drug-style phases.
  • Pivotal design varies by classification: PMA demands the highest evidence bar, De Novo novel classification, 510(k) equivalence — the pipeline's value path depends on the expected track.
  • RWE studies (registries, claims analyses) increasingly support coverage and label expansion; treat them as pipeline assets with their own timelines.
  • Post-market obligations (surveillance studies, MDR reporting) shape long-term liability and the re-approval path.
  • Reimbursement-aware framing: pipeline value assumes a coverage path; an asset without one is discounted.
  • Grounding detail lives in references/knowledge-frameworks.md.

Data Source Priority

  1. get_company_devices / search_universe_devices — asset inventory from the med universe.
  2. search_clinical_trials / get_clinical_trial — study stage, design type, status, enrollment.
  3. get_device_decision — decision history and upcoming decisions per device.
  4. Knowledge layer: search_knowledge_entries for framework grounding.

Methodology

Retrieval Scope

structured_only

Retrieval Strategy

  1. Pull asset inventory (get_company_devices), cross-check the universe (search_universe_devices).
  2. Enrich per asset with study records (search_clinical_trials) — stage, design type, status-diff.
  3. Pull decision history and upcoming dates (get_device_decision).
  4. Flag post-market obligations and RWE study presence per asset.
  5. Size each asset (peak x POS); ground in knowledge entries.

Temporal Scope

See frontmatter temporal_scope block. Device development and post-market windows span years; history may reach back 8-12 quarters.

Tool Allowlist

See frontmatter allowed_tools.

Protocol

  1. Asset enumeration
  2. Stage and design-cycle mapping
  3. Decision-track alignment
  4. Post-market and RWE overlay
  5. Risk-adjusted synthesis

Modes

  • Phase scan (default): all devices by stage with next catalyst and expected track.
  • Design cycle: design-iteration state, freezes, and submission readiness.
  • Post-market: obligations, surveillance state, and RWE support.

Tool Fallbacks

Failure Fallback
get_company_devices empty search_universe_devices by company or indication; annotate coverage_gap
No trial rows Mark stage undisclosed; do not guess pivotal vs feasibility
No decision history Flag the submission track unknown; state both possibilities
Knowledge tools empty Proceed with structured data only

Output File

{ticker}/{YYYY-MM-DD_HHMM}_pipeline-devices_{affix}.md

Output Structure

  1. Executive Summary — pipeline stance in 2-3 sentences
  2. Asset Table — stage, design type, expected track, next catalyst
  3. Design-Cycle Read — iteration state, freezes, submission readiness
  4. Post-Market & RWE — obligations, surveillance, registries
  5. Risk-Adjusted Sizing — peak x POS with reimbursement framing
  6. Coverage Gaps — missing records, undisclosed stage, degraded modes

Error Handling

Error Fallback
Stage unknown Mark "undisclosed"; do not guess
Classification ambiguous State the evidence-bar difference across tracks
No catalysts found Say so explicitly; note the pipeline may be early-stage

Memory Load

See contracts/memory-load.md.

Snapshot

See contracts/snapshot-synthesis.md.

Final Summary (TUI)

Include ### Key Citations block with 0-10 clickable /v/ URLs.

References

  • contracts/citation-and-memory.md
  • contracts/output-frontmatter-schema.md
  • contracts/memory-load.md
  • contracts/snapshot-synthesis.md
  • contracts/preflight.md
  • references/knowledge-frameworks.md
Files (agentii-investment-intelligence)
  • references
    • knowledge-frameworks.md 4.6 KB
      # Pipeline Devices — Knowledge Frameworks
      
      Static grounding for `pipeline-devices` (spec 055). Runtime records are retrieved via the knowledge tools and cited with /v/ URLs; this file carries the device stage ladder, design-iteration discipline, RWE ladder, post-market obligations, and failure modes. Shared regulatory scaffolding (scrutiny axes) lives in `../../fda-catalyst-analysis/references/knowledge-frameworks.md`.
      
      ## Device Stage Ladder (iteration, not phases)
      
      - **Feasibility**: first-in-human, small N, safety and signal — the design is not yet frozen.
      - **Pivotal**: registrational study sized to the evidence bar of the expected track: PMA (highest), De Novo (novel classification), 510(k) (equivalence — often no pivotal at all).
      - **Submission / decision**: PMA approval, De Novo grant, or 510(k) clearance; the track determines the size of the binary event.
      - **Post-market**: surveillance studies, MDR reporting, next-generation design work — the pipeline does not end at approval.
      
      Devices iterate: version freezes, design changes, and equivalence testing between generations are the milestones. A device "pipeline" is a sequence of design cycles, not a fixed phase ladder.
      
      ## Design-Iteration Discipline
      
      - Track the current design version per asset and whether it is frozen (a freeze is the submission-readiness signal).
      - Design changes mid-pivotal reset evidence: flag any asset that changed design after study start.
      - Next-generation programs: the v2 asset cannibalizes the v1 installed base — model them together, not separately.
      
      ## RWE Ladder
      
      - **Registries**: longitudinal product-outcome data, often conditionally required post-approval.
      - **Claims analyses**: utilization and outcome signals at scale, supporting label expansion and coverage.
      - **Post-approval studies**: FDA-required commitments (conditions of approval) with their own timelines.
      - RWE is a pipeline asset: it extends labels, supports coverage, and feeds the next design cycle.
      
      ## Post-Market Obligations
      
      - PMAs carry conditions of approval and surveillance requirements; missing them risks recall-class escalation.
      - MDR trends are early-warning data: a rising adverse-event series precedes formal action.
      - Installed-base economics: the obligation set scales with the base — utilization data settles whether the base is healthy.
      
      ## POS / Scenario Discipline (cross-cutting)
      
      Unadjusted peak x POS = the modeled number; both terms shown; POS changes logged with reasons. Reimbursement is a probability input: an asset without a plausible coverage path gets a discounted POS. Bull/base/bear with named-driver grids (track outcome, coverage timing, adoption rate); explicit abstention where unquantifiable.
      
      ## Commercial Context (P1 launch board, applied forward)
      
      Consensus sales ÷ ASP ÷ procedure ramp → required procedure volume → linear path vs at least two named same-category adoption curves. ASP carries label-expansion annotations: each expansion re-prices the opportunity. Installed base, placements, procedures, and utilization are the forward vocabulary for every pivotal asset.
      
      ## Failure Modes
      
      - **Applying drug-phase labels to devices**: feasibility/pivotal stages are iteration points, not fixed phases; a "Phase II device" mislabels the evidence bar.
      - **Ignoring the design-freeze signal**: submission readiness is the freeze, not the enrollment count.
      - **Sizing without the reimbursement gate**: approval-track value assumed, coverage path absent.
      - **Ignoring post-market obligations**: the liability tail is part of pipeline value.
      - **v1/v2 double-counting**: next-generation programs modeled independently of the base they cannibalize.
      
      ## Structured Data Surfaces
      
      - `get_company_devices` / `search_universe_devices` — device inventory and owner joins.
      - `search_clinical_trials` / `get_clinical_trial` — study stage, design type, status, enrollment.
      - `get_device_decision` — decision history and upcoming decisions per device.
      
      ## Cross-Cutting Habits
      
      - **Buy-side lens**: track where investor attention sits; the client-question pattern — answer the most common question directly (e.g. "has the design frozen, or is another iteration coming?"); per-asset bull/bear pivot conditions.
      - **Living-thesis loop**: estimates move first, ratings last; append exhibits to the prior note, never rewrite; design-version history persists across updates.
      - **Badge mapping (FR-092)**: verifiable facts `[FACT]`, derived arithmetic `[DEDUCTED]`, judgments `[VIEW]` — with a Category/Count/% summary table.
      
      ## Authoring-time citations
      
      Spec 055 med strategies and cases are linked here as they reach `approved` status; at runtime retrieve via `search_knowledge_entries` and cite with /v/ URLs.
      
    • modes.md 430 B
      # pipeline-devices — Analyst Mode Definitions
      
      Derived from the skill's ## Modes section (spec 046 M1).
      
      ### Mode: phase-scan
      
      **Objective**: All devices by stage with next catalyst and expected regulatory track.
      
      ### Mode: design-cycle
      
      **Objective**: Design-iteration state, version freezes, and submission readiness.
      
      ### Mode: post-market
      
      **Objective**: Surveillance obligations, recall posture, and RWE support per asset.
      
  • SKILL.md 6.2 KB
    ---
    name: pipeline-devices
    description: "Device pipeline analysis: feasibility and pivotal study stages, design-iteration cycles, RWE studies, and post-market obligations, with reimbursement-aware value framing and decision-track awareness across the med universe."
    sectors: [med.medicines_biotech, med.medical_devices]
    multi_ticker_semantics: single_target
    temporal_scope:
      default_quarters: 8
      max_quarters: 20
      description: "Long-horizon pipeline window default 8 quarters; up to 20 for multi-year device development and post-market programs."
    allowed_tools:
      - get_company_devices
      - search_universe_devices
      - search_clinical_trials
      - get_clinical_trial
      - get_device_decision
      - search_companies
      - get_company_profile
      - search_knowledge_entries
    retrieval_scope: structured_only
    min_tool_diversity: 3
    parameter_free: false
    ---
    
    > Methodology inspired by publicly taught medtech pipeline frameworks; all text is an original paraphrase.
    
    ## Defaults
    
    | Parameter | Default Value | Rationale |
    |-----------|---------------|-----------|
    | asset_scope | all disclosed devices | Full-pipeline enumeration first |
    | stage_lens | feasibility + pivotal | Design-iteration stages, not drug-phase labels |
    | reimbursement_aware | true | Value framed against coverage paths, not raw approval |
    | post_market_scan | true | Obligations and surveillance state surfaced |
    | value_frame | risk-adjusted | Modeled value = unadjusted peak x POS, both shown |
    
    ## Preflight
    
    Run canonical pre-flight per `contracts/preflight.md`. Propagate X-Agentii-Trace per `contracts/x-agentii-trace-header.md`. Confirm ticker resolution via `search_companies` before asset queries.
    
    ## Triggers
    
    - "Analyze [ticker]'s device pipeline."
    - "What is in [ticker]'s feasibility and pivotal portfolio?"
    - "Where is each of [ticker]'s devices in its design cycle?"
    - "Which of [ticker]'s programs are approaching submission?"
    - "What RWE studies support [ticker]'s devices?"
    - "What post-market obligations does [ticker] carry?"
    - "Risk-adjust [ticker]'s device pipeline."
    - "What is the next catalyst for each of [ticker]'s devices?"
    - "How does [ticker]'s device pipeline compare to peers?"
    - "Which device classifications (PMA/De Novo/510(k)) map to [ticker]'s pipeline?"
    - "Map [ticker]'s devices by clinical stage and indication."
    - "What does [ticker]'s pipeline say about its reimbursement path?"
    
    ## Production Grounding
    
    - Device stage ladder: feasibility (first-in-human, small N) → pivotal (registrational) → submission (PMA / De Novo / 510(k)) → post-market. Devices iterate through design versions; design freezes and iteration cycles are the pipeline milestones, not drug-style phases.
    - Pivotal design varies by classification: PMA demands the highest evidence bar, De Novo novel classification, 510(k) equivalence — the pipeline's value path depends on the expected track.
    - RWE studies (registries, claims analyses) increasingly support coverage and label expansion; treat them as pipeline assets with their own timelines.
    - Post-market obligations (surveillance studies, MDR reporting) shape long-term liability and the re-approval path.
    - Reimbursement-aware framing: pipeline value assumes a coverage path; an asset without one is discounted.
    - Grounding detail lives in `references/knowledge-frameworks.md`.
    
    ## Data Source Priority
    
    1. `get_company_devices` / `search_universe_devices` — asset inventory from the med universe.
    2. `search_clinical_trials` / `get_clinical_trial` — study stage, design type, status, enrollment.
    3. `get_device_decision` — decision history and upcoming decisions per device.
    4. Knowledge layer: `search_knowledge_entries` for framework grounding.
    
    ## Methodology
    
    ### Retrieval Scope
    structured_only
    
    ### Retrieval Strategy
    1. Pull asset inventory (`get_company_devices`), cross-check the universe (`search_universe_devices`).
    2. Enrich per asset with study records (`search_clinical_trials`) — stage, design type, status-diff.
    3. Pull decision history and upcoming dates (`get_device_decision`).
    4. Flag post-market obligations and RWE study presence per asset.
    5. Size each asset (peak x POS); ground in knowledge entries.
    
    ### Temporal Scope
    See frontmatter temporal_scope block. Device development and post-market windows span years; history may reach back 8-12 quarters.
    
    ### Tool Allowlist
    See frontmatter allowed_tools.
    
    ### Protocol
    1. Asset enumeration
    2. Stage and design-cycle mapping
    3. Decision-track alignment
    4. Post-market and RWE overlay
    5. Risk-adjusted synthesis
    
    ## Modes
    
    - **Phase scan** (default): all devices by stage with next catalyst and expected track.
    - **Design cycle**: design-iteration state, freezes, and submission readiness.
    - **Post-market**: obligations, surveillance state, and RWE support.
    
    ## Tool Fallbacks
    
    | Failure | Fallback |
    |---------|----------|
    | get_company_devices empty | `search_universe_devices` by company or indication; annotate coverage_gap |
    | No trial rows | Mark stage undisclosed; do not guess pivotal vs feasibility |
    | No decision history | Flag the submission track unknown; state both possibilities |
    | Knowledge tools empty | Proceed with structured data only |
    
    ## Output File
    
    `{ticker}/{YYYY-MM-DD_HHMM}_pipeline-devices_{affix}.md`
    
    ## Output Structure
    
    1. **Executive Summary** — pipeline stance in 2-3 sentences
    2. **Asset Table** — stage, design type, expected track, next catalyst
    3. **Design-Cycle Read** — iteration state, freezes, submission readiness
    4. **Post-Market & RWE** — obligations, surveillance, registries
    5. **Risk-Adjusted Sizing** — peak x POS with reimbursement framing
    6. **Coverage Gaps** — missing records, undisclosed stage, degraded modes
    
    ## Error Handling
    
    | Error | Fallback |
    |-------|----------|
    | Stage unknown | Mark "undisclosed"; do not guess |
    | Classification ambiguous | State the evidence-bar difference across tracks |
    | No catalysts found | Say so explicitly; note the pipeline may be early-stage |
    
    ## Memory Load
    
    See `contracts/memory-load.md`.
    
    ## Snapshot
    
    See `contracts/snapshot-synthesis.md`.
    
    ## Final Summary (TUI)
    
    Include ### Key Citations block with 0-10 clickable /v/ URLs.
    
    ## References
    
    - `contracts/citation-and-memory.md`
    - `contracts/output-frontmatter-schema.md`
    - `contracts/memory-load.md`
    - `contracts/snapshot-synthesis.md`
    - `contracts/preflight.md`
    - `references/knowledge-frameworks.md`
    

Comments (0)

Sign in to join the conversation.

No comments yet.

Reviews (0)

No reviews yet.

Related